People · Operator
Named in public records as an officer, director or promoter · active 2008–2025 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Iambic Therapeutics, Inc. | — | Biotechnology | Series D+ | $240.9M | $697.8M | 2023 |
| SutroVax, Inc. | — | Biotechnology | Series D+ | $205.9M | $4.5B | 2017 |
| CymaBay Therapeutics, Inc. | — | Biotechnology | Series B | $90.6M | $12.9M | 2008 |
| Vera Therapeutics, Inc. | — | Biotechnology | Series C | $70.7M | $2.6B | 2020 |
| Attenua, Inc. | — | Pharmaceuticals | Series B | $15.2M | $517.0M | 2018 |
| Somaxon Pharmaceuticals, Inc. | — | Pharmaceuticals | Series A | $6.0M | $185.8M | 2009 |
Kurt Von Emster at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Kurt Von Emster on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Patrick Enright | 2 | 10 |
| David F Hale | 1 | 16 |
| Beth Seidenberg | 1 | 15 |
| Rishi Gupta | 1 | 12 |
| Patrick Heron | 1 | 11 |
| BRADLEY BOLZON | 1 | 10 |
| Jishnu Bhattacharjee | 1 | 9 |
| Patrick J. Heron | 1 | 7 |
| Peter Hirth | 1 | 7 |
| Maha Katabi | 1 | 6 |
| R. Jacob Vogelstein | 1 | 6 |
| Anthony Evnin | 1 | 6 |
| SCOTT MORRISON | 1 | 6 |
| Robert Zerbe | 1 | 5 |
| Carl Goldfischer | 1 | 5 |
| Jesse I. Treu | 1 | 5 |
| Thomas Miller | 1 | 5 |
| Tracy Saxton | 1 | 5 |
| William Rastetter | 1 | 4 |
| Shalini Sharp | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.